- Trials with a EudraCT protocol (61)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
61 result(s) found for: Acromegaly.
Displaying page 3 of 4.
EudraCT Number: 2019-000591-42 | Sponsor Protocol Number: ISIS766720-CS3 | Start Date*: 2019-06-14 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Extension Trial of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor Administered Monthly Subcutaneously to Patients with Acromegaly Being Treated with Long-Acting ... | |||||||||||||
Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) PL (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000737-31 | Sponsor Protocol Number: OOC-ACM-303 | Start Date*: 2017-10-27 | |||||||||||
Sponsor Name:Chiasma, Inc. | |||||||||||||
Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical c... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) PL (Completed) IT (Completed) BG (Completed) LV (Completed) SI (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016722-13 | Sponsor Protocol Number: CSOM230C2402 | Start Date*: 2010-06-10 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanr... | |||||||||||||
Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) NO (Completed) BE (Completed) DE (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002619-25 | Sponsor Protocol Number: P061012 | Start Date*: 2007-09-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: "Physiopathologie de la rétention rénale de sodium dans l'acromégalie" -Etude ACROMENAC | |||||||||||||
Medical condition: Acromégalie | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004782-14 | Sponsor Protocol Number: THIGHT_2 | Start Date*: 2014-03-20 |
Sponsor Name:Medizinische Universität Wien, KIMIII, Abteilung für Endokrinologie und Stoffwechsel | ||
Full Title: Assessment of changes in metabolic activity in liver & skeletal muscle in patients suffering from acromegaly - a 31P/1H magnetic resonance spectroscopy pilot study | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003496-20 | Sponsor Protocol Number: LAR/005 | Start Date*: 2006-10-31 |
Sponsor Name:Oxford Radcliffe Hospitals NHS trust | ||
Full Title: The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured s... | ||
Medical condition: Acromegaly, overproduction of growth hormone by (almost always) a benign pituitary tumour. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003183-31 | Sponsor Protocol Number: DSC/13/2984/05 | Start Date*: 2014-02-25 |
Sponsor Name:ITALFARMACO S.p.A. | ||
Full Title: A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients. | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Completed) PL (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004300-36 | Sponsor Protocol Number: acmed 01 | Start Date*: 2006-02-27 |
Sponsor Name:Plymouth Hospital NHS Trust, R&D dept | ||
Full Title: Use of somatostatin analogue therapy as primary medical treatment of acromegaly | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004259-22 | Sponsor Protocol Number: ISIS766720-CS2 | Start Date*: 2018-06-05 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered... | |||||||||||||
Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004904-19 | Sponsor Protocol Number: 04_ENDO_44 | Start Date*: 2005-07-11 |
Sponsor Name:Christie Hospital | ||
Full Title: A two-centre, open label study of weekly pegvisomant treatment for patients with acromegaly | ||
Medical condition: This study will investigate the efficacy of once-weekly pegvisomant treatment in patients with acromegaly who have already achieved disease control on daily pegvisomant. The attraction of once wee... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021008-77 | Sponsor Protocol Number: PASIREOTIDE/01/2010 | Start Date*: 2011-08-22 |
Sponsor Name:Göteborgs Universitet, Göteborg Sweden | ||
Full Title: A MULTI - CENTER OPEN LABEL PHASE II (B) STUDY TO ASSESS EFFECTS OF SOM230 ON CARDIOVASCULAR PARAMETERS IN ACROMEGALIC PATIENTS | ||
Medical condition: Adult patients 18 to 80 years of age with diagnosed acromegaly eligible for treatment with a somatostatin analogue and not on previous pharmacological treatment for acromegaly. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002916-16 | Sponsor Protocol Number: CSOM230B2219 | Start Date*: 2014-08-19 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s ... | ||||||||||||||||||
Medical condition: Cushing's disease and acromegaly | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) DK (Completed) PL (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005855-14 | Sponsor Protocol Number: C2L-OCT-01 PR-301 | Start Date*: 2007-02-22 |
Sponsor Name:Ambrilia Biopharma Inc. | ||
Full Title: OPEN LABEL, RANDOMIZED STUDY COMPARING THE BIOLOGICAL EFFICACY AND SAFETY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 42 D... | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) SK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002219-41 | Sponsor Protocol Number: NL49517 | Start Date*: 2015-07-22 |
Sponsor Name:Erasmus Medical Centre | ||
Full Title: A prospective single-centre double blind randomized study on the efficacy and safety of 4 weekly pasireotide LAR administration in combination with or without weekly pegvisomant in previously contr... | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004231-31 | Sponsor Protocol Number: MEC2011pegvqol | Start Date*: 2013-07-22 |
Sponsor Name:Erasmus University Medical Centre Rotterdam | ||
Full Title: Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analogues | ||
Medical condition: acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001108-35 | Sponsor Protocol Number: NRA 6290010 | Start Date*: 2006-07-03 | |||||||||||
Sponsor Name:Clinic of University of Wuerzburg | |||||||||||||
Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY | |||||||||||||
Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000267-84 | Sponsor Protocol Number: CSOM230B2412 | Start Date*: 2013-06-07 | ||||||||||||||||
Sponsor Name:NOVARTIS FARMA | ||||||||||||||||||
Full Title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continue... | ||||||||||||||||||
Medical condition: Cushing’s disease Neuroendocrine tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) BE (Completed) ES (Completed) GR (Completed) FR (Completed) PL (Completed) PT (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000831-34 | Sponsor Protocol Number: GoforGH | Start Date*: 2022-01-11 |
Sponsor Name:Medical University of Vienna | ||
Full Title: InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans | ||
Medical condition: Healthy subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000864-82 | Sponsor Protocol Number: hydrocortisone | Start Date*: 2011-12-22 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: A randomized double blind cross-over study of the effects of low dose and high dose hydrocortisone replacement therapy on cognition, quality of life, metabolic profile and somatosensation in patien... | |||||||||||||
Medical condition: Secondary adrenal insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004413-15 | Sponsor Protocol Number: CSOM230B2209 | Start Date*: 2006-06-07 | |||||||||||
Sponsor Name:Cedars Sinai Medical Center | |||||||||||||
Full Title: Effectiveness of SOM230 In Treating Non-Functioning Pituitary Adenomas | |||||||||||||
Medical condition: non-functioning pitiutary adenomes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
